# Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

> **NCT04705831** · PHASE2 · COMPLETED · sponsor: **IMMUNOe Research Centers** · enrollment: 40 (actual)

## Conditions studied

- Post-Viral Fatigue Syndrome
- Post-Viral Disorder (Disorder)
- Covid19

## Interventions

- **DRUG:** Ruconest

## Key facts

- **NCT ID:** NCT04705831
- **Lead sponsor:** IMMUNOe Research Centers
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2024-03-30
- **Final completion:** 2024-07-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04705831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04705831, "Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04705831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*